Brian Østergaard
Impact in
- Hematology top 5%
- Multiple Myeloma Research and Treatments
-
- Peptidase Inhibition and Analysis
- Bone health and treatments
Papers in ⓘ
- Oncology 15
- Cancer Treatment and Pharmacology 8
- Bone health and treatments 7
- Hematology 14
- Multiple Myeloma Research and Treatments 14
- Co-authors
- Niels Abildgaard (16 shared papers)Jon Thor Asmussen (1 shared paper)Heinz-Peter Schlemmer (1 shared paper)Frédéric Lecouvet (1 shared paper)Anwar R. Padhani (1 shared paper)Stefan Delorme (1 shared paper)Jens Hillengaß (1 shared paper)Lia A. Moulopoulos (1 shared paper)
- Journals
- European Journal Of Haematology (3 papers)Radiology (1 paper)European Journal of Nuclear Medicine and Molecular Imaging (1 paper)Nuclear Medicine Communications (1 paper)Hematological Oncology (1 paper)
- Partner nations
- United StatesDenmarkNorway
In The Last Decade
Brian Østergaard
20 papers receiving 420 citations
Peers
Comparison fields: 5 of 40
- Hematology 244
- Oncology 159
- Radiology, Nuclear Medicine and Imaging 115
- Emergency Medicine 42
- Hepatology 33
Countries citing papers authored by Brian Østergaard
This map shows the geographic impact of Brian Østergaard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Østergaard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Østergaard more than expected).
Fields of papers citing papers by Brian Østergaard
This network shows the impact of papers produced by Brian Østergaard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Østergaard. The network helps show where Brian Østergaard may publish in the future.
Co-authors
The 25 scholars most cited alongside Brian Østergaard, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 218 | |
| 2 | 2008 | 45 | |
| 3 | 2015 | 45 | |
| 4 | 2015 | 31 | |
| 5 | 2020 | 15 | |
| 6 | Prognostic significance of 18F-sodium fluoride in newly diagnosed multiple myeloma patients. | 2020 | 14 |
| 7 | 2018 | 13 | |
| 8 | Correlation of whole-bone marrow dual-time-point 18F-FDG, as measured by a CT-based method of PET/CT quantification, with response to treatment in newly diagnosed multiple myeloma patients. | 2020 | 8 |
| 9 | 2019 | 8 | |
| 10 | Correlation of Dual Time Point FDG-PET with Response to Chemotherapy in Multiple Myeloma | 2017 | 6 |
| 11 | Changes in bone marrow FDG uptake in multiple myeloma patients before and after treatment | 2018 | 5 |
| 12 | 2020 | 5 | |
| 13 | Quantification of the total bone marrow activity with FDG-PET in multiple myeloma before and after treatment: comparison with a control group | 2017 | 3 |
| 14 | Feasibility of using global FDG uptake in bone marrow to assess treatment of multiple myeloma | 2017 | 2 |
| 15 | Comparison of global uptake of NaF-PET/CT in whole-body bone in multiple myeloma and healthy controls | 2017 | 1 |
| 16 | Global quantification of NaF in the skeleton: assessing bone formation in multiple myeloma patients before and after treatment | 2017 | 1 |
| 17 | Baseline global splenic uptake of FDG in multiple myeloma patients: a higher uptake is associated with inferior overall survival | 2019 | 1 |
| 18 | Correlation between whole-bone marrow 18F-FDG uptake and prognostic factors in newly diagnosed multiple myeloma patients | 2020 | 1 |
| 19 | Assessment of bone turnover in multiple myeloma patients before and after treatment | 2018 | 1 |
| 20 | Evaluation of myeloma bone disease by means of 18F-sodium fluoride PET/CT | 2019 | 1 |
About Brian Østergaard
Brian Østergaard is a scholar working on Oncology, Hematology, Radiology, Nuclear Medicine and Imaging, Genetics and Emergency Medicine, having authored 21 papers that have together received 424 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (14 papers), Cancer Treatment and Pharmacology (8 papers), Bone health and treatments (7 papers), Medical Imaging Techniques and Applications (5 papers), Hematological disorders and diagnostics (4 papers), Radiopharmaceutical Chemistry and Applications (4 papers), Protein Degradation and Inhibitors (2 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (2 papers). The work is most often cited by research in Hematology (244 citations), Oncology (159 citations), Radiology, Nuclear Medicine and Imaging (115 citations), Emergency Medicine (42 citations) and Hepatology (33 citations). Brian Østergaard has collaborated with scholars based in United States, Denmark and Norway. Frequent co-authors include Niels Abildgaard, Jon Thor Asmussen, Heinz-Peter Schlemmer, Frédéric Lecouvet, Anwar R. Padhani, Stefan Delorme, Jens Hillengaß, Lia A. Moulopoulos, Martin Kaiser and Ola Landgren. Their work appears in journals such as European Journal Of Haematology, Radiology, European Journal of Nuclear Medicine and Molecular Imaging, Nuclear Medicine Communications and Hematological Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.